The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

After a dramatic week of AI stock swings and major tech earnings, it’s time for another round of tech results. Despite ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company (NYSE:LLY) is focusing on advancing its pipeline, particularly in the obesity drug market, which analysts predict could be worth $200 billion by 2031. Overall LLY ranks 4th ...

receptor agonist drug portfolio. In the past 12 months, LLY has surged by over 25.6%. In fiscal Q4 2024, Eli Lilly and Company (NYSE:LLY) generated $11.4 billion in revenue, reflecting a 20.5% ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug ...

Eli Lilly (LLY) reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2%. But the company missed on GLP-1 ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity drugs. The pharma group ...

Eli Lilly has unveiled a $2.5 billion ... It was joined last year by Roche's Itovebi (inavolisib), the company's second candidate after its lead drug in the class (taselisib) was abandoned on ...